Prucalopride is a serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults. It is available as tablets for oral use. MedsAcross supplies Prucalopride for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
MOTEGRITY ® is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. MOTEGRITY is a serotonin-4 (5-HT 4 ) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Source: US FDA prescribing information
Prucalopride, a selective serotonin type 4 (5-HT 4 ) receptor agonist, is a gastrointestinal (GI) prokinetic agent that stimulates colonic peristalsis (high-amplitude propagating contractions [HAPCs]), which increases bowel motility. Prucalopride was devoid of effects mediated via 5-HT 2A, 5-HT 2B, 5-HT 3, motilin or CCK-A receptors in vitro at concentrations exceeding 5-HT 4 receptor affinity by 150-fold or greater. In isolated GI tissues from various animal species, prucalopride facilitated acetylcholine release to enhance the amplitude of contractions and stimulate peristalsis. In rats and dogs, prucalopride stimulated gastrointestinal motility with contractions starting from the proximal colon to the anal sphincter.
Source: US FDA prescribing information
MOTEGRITY can be taken with or without food. The recommended dosage by patient population is shown in Table 1. Table 1: Recommended Dosage Regimen and Dosage Adjustments by Population Population with CIC Recommended Oral Dose Regimen Adults 2 mg once daily Patients with severe renal impairment (creatinine clearance (CrCL) less than 30 mL/min). 1 mg once daily Take with or without food. Recommended dosage by patient population: Population with CIC Recommended Oral Dose Regimen Adults 2 mg once daily. Patients with severe renal impairment (creatinine clearance (CrCL) less than 30 mL/min) 1 mg once daily.
Source: US FDA prescribing information
MOTEGRITY is contraindicated in patients with: A history of hypersensitivity to MOTEGRITY. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed. Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum. Hypersensitivity to MOTEGRITY.
Source: US FDA prescribing information
Suicidal Ideation and Behavior: Monitor patients for suicidal ideation and behavior as well as self-injurious ideation and new-onset or worsening of depression. Instruct patients to discontinue MOTEGRITY immediately and contact their healthcare provider if they experience any unusual changes in mood or behavior, or they experience emerging suicidal thoughts or behaviors.
Source: US FDA prescribing information
Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.
Source: US FDA prescribing information
Store MOTEGRITY at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (between 59°F to 86°F). Store MOTEGRITY in the original container to protect from moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Prucalopride, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Prucalopride 1 mg tabletOralGeneric name | — | US FDA | Available on request |
| Prucalopride 2 mg tabletOralGeneric name | — | US FDA | Available on request |
| Motegrity 1 mg tabletOral | Takeda Pharmaceuticals | US FDA | Available on request |
| Motegrity 2 mg tabletOral | Takeda Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 4 presentations of Prucalopride and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Prucalopride, including Motegrity.
Yes. The US FDA first approved Prucalopride on 14 December 2018, according to Drugs@FDA.
Yes. Prucalopride has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Prucalopride is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Prucalopride is classified under ATC code A06AX05 (Prucalopride).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.